Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats

European Journal of Pharmacology

Volumn 403, Issue 1-2, 2000, Pages 27-35

  Jacke, Kerstin ^a   Witte, Klaus ^a   Huser, Lutz ^a   Behrends, Sönke ^b   Lemmer, Björn ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Aorta; Guanylyl cyclase; Hypertension; Renin angiotensin system; Soluble; Superoxide anion

Indexed keywords

AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GUANYLATE CYCLASE; NITRIC OXIDE; RENIN; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBUNIT; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE;

AGING; AMLODIPINE; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTA, THORACIC; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; GUANYLATE CYCLASE; HYDRAZINES; HYPERTENSION; MALE; NITROGEN OXIDES; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOLUBILITY;

EID: 0034283855     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00577-X     Document Type: Article

References (33)

1. Ackermann H. Biometrische Analyse von Stichproben. 7th edn. 1997;Epsilon Verlag, Hochheim, Darmstadt.
2. Bachmann S., Peters J., Engler E., Ganten D., Mullins J. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int. 41:1992;24-36.
3. Bauersachs J., Bouloumié A., Fraccarollo D., Hu K., Busse R., Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression. Circulation. 100:1999;292-298.
4. Behrends S., Steenpass A., Porst H., Scholz H. Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum. Biochem. Pharmacol. 59:2000;713-717.
5. Brandes R., Kim D., Schmitz-Winnenthal F., Amidi M., Gödecke A., Mülsch A., Busse R. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice. Hypertension. 35:2000;231-236. part 2.
6. Busse R., Fleming I. Pulsatile stretch and shear stress: physical stimuli determining the production of endothelium-derived relaxing factors. J. Vasc. Res. 35:1998;73-84.
7. Chen L., Daum G., Fischer J.W., Hawkins S., Bochaton-Piallat M.L., Gabbiani G., Clowes A.W. Loss of expression of the β subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ. Res. 86:2000;520-525.
8. Dominiczak A.F., Bohr D.F. Nitric oxide and its putative role in hypertension. Hypertension. 25:1995;1202-1211.
9. Filippov G., Bloch D.B., Bloch K.D. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J. Clin. Invest. 100:1997;942-948.
10. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1994;1141-1148.
11. Gupta G., Azam M., Yang L., Danziger R.S. The β2 subunit inhibits stimulation of the α1/β1 form of soluble guanylyl cyclase by nitric oxide. J. Clin. Invest. 100:1997;1488-1492.
12. Klöß S., Bouloumié A., Mülsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension. 35:2000;43-47.
13. Kojda G., Kottenberg K., Hacker A., Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm. Acta Helv. 73:1998;27-35.
14. Lee M., Böhm M., Paul M., Bader M., Ganten U., Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am. J. Physiol. 270:1996;E919-E929.
15. Lemmer B., Mattes A., Böhm M., Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension. 22:1993;97-101.
16. Mattes A., Witte K., Hohmann W., Lemmer B. Pharmfit - a nonlinear fitting program for pharmacology. Chronobiol. Int. 8:1991;460-476.
17. McIntyre M., Bohr D., Dominiczak A. Endothelial function in hypertension. Hypertension. 34:1999;539-545.
18. Minor R.L., Myers P.R., Guerra R., Bates J.N., Harrison D.G. Diet-induced atherosklerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest. 86:1990;2109-2116.
19. Morley D., Keefer L. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J. Cardiovasc. Pharmacol. 22:1993;3-9. Suppl. 7.
20. Ohta K., Kim S., Wanibuchi H., Ganten D., Iwao H. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mRen2)27 transgenic rats. Circulation. 94:1996;785-791.
21. Pinto Y.M., Buikema H., van Gilst W.H., Scholtens E., van Geel P.P., de Graeff P.A., Wagner J., Paul M. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J. Mol. Med. 75:1997;371-377.
22. 1 receptors. Hypertens. Res. 19:1996;201-206.
23. Sander M., Ganten D., Mellon S.H. Role of adrenal renin in the regulation of adrenal steroidogenesis by corticotropin. Proc. Natl. Acad. Sci. U. S. A. 91:1994;148-152.
24. Simchon S., Manger W., Blumberg G., Brensilver J., Cortell S. Impaired renal vasodilatation and urinary cGMP excretion in Dahl salt-sensitive rats. Hypertension. 27:1996;653-657.
25. Stone J.R., Marletta M.A. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry. 33:1994;5636-5640.
26. Struijker-Boudier H.A.J., van Essen H., Fazzi G., De Mey J.G.R., Qui H.Y., Lévy B. Disproportional arterial hypertrophy in hypertensive mRen-2 transgenic rats. Hypertension. 28:1996;779-784.
27. Vaziri N., Wang X. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension. 34:1999;1237-1241.
28. Véniant M., Whitworth C., Ménard L., Sharp M., Gonzales M.F., Bruneval P., Mullins J. Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mREN2)27 rats. Am. J. Hypertens. 8:1995;1167-1176.
29. Villarreal F.J., Mackenna D.A., Omens J.H., Dillmann W.H. Myocardial remodeling in hypertensive Ren-2 transgenic rats. Hypertension. 25:1995;98-104.
30. Wattanapitayakul S.K., Weinstein D.M., Holycross B.J., Bauer J.A. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J. 14:2000;271-278.
31. Witte K., Schnecko A., Zuther P., Lemmer B. Contribution of the nitric oxide-guanylyl cyclase system to circadian regulation of blood pressure in normotensive Wistar-Kyoto rats. Cardiovasc. Res. 30:1995;682-688.
32. Witte K., Schnecko A., Perbandt K., Höfer S., Lemmer B. Signal transduction in cardiac and vascular tissue from normotensive and transgenic hypertensive TGR(mREN2)27 rats. Eur. J. Pharmacol. 341:1998;337-341.
33. Witte K., Schnecko A., Schmidt T., Voll C., Kränzlin B., Lemmer B. Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats. Gen. Pharmacol. 33:1999;423-430.